Oral Chinese Herbal Medicine for Treatment of Dilated Cardiomyopathy: A Systematic Review and Meta‐Analysis

Zhu, Yushuo; Li, Yunlun; Ju, Jianqing; Du, Feng; Yuelong, Zang; Wang, Xiaobing; Sheng, Jie

doi:10.1155/2016/1819794

Cited by 10 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple meta-analyses and systematic reviews have confirmed the effectiveness and safety of traditional Chinese medicine (TCM) in treating DCM. A meta-analysis constituting 21 RCTs involving 1,566 patients revealed that oral Chinese herbal medicine effectively improves overall efficacy, LVEF, LVEDD, stroke volume (SV), BNP, and 6MWD in the treatment of DCM ( Zhu et al, 2016 ), which was consistent with our results. However, BNP, LVEF, SV, and 6MWD represented high heterogeneity in their meta-analysis.…”

Section: Discussionsupporting

confidence: 90%

Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials

Wei

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Qili Qiangxin Capsule (QQC), a Chinese patent medicine, is clinically effective in treating dilated cardiomyopathy (DCM). However, the meta-analysis of QCC combined with conventional western medicine (CWM) on DCM remains unexplored. This study aimed to systematically evaluate the efficacy and safety of QCC in the treatment of DCM.Methods: Searched the studies of the combination of QQC and CWM in the treatment of DCM, from databases like PubMed, Cochrane Library, Web of Science, Wan Fang Databases, Chinese Biomedical Literature Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, prior to 15 January 2022. Two reviewers respectively regulated research selection, data extraction, and risk of bias assessment. Review Manager Software 5.4 was used for meta-analysis. Furthermore, GRADE pro3.6.1 software was selected to grade the current evidence in our findings. This meta-analysis has been registered in PROSPERO (CRD42022297906).Results: There were 35 studies pertaining to 3,334 patients included. The meta-analysis showed compared with CWM alone, the combination therapy had significant advantages in improving the clinical efficiency rate (RR = 1.24, 95% CI: 1.19 to 1.29, p < 0.00001), 6 min walking distance (6MWD) (MD = 41.93, 95%CI: 39.82 to 44.04, p < 0.00001), superior in ameliorating the left ventricular ejection fraction (LVEF) (MD = 5.73, 95%CI: 4.70 to 6.77, p < 0.00001), left ventricular end-diastolic dimension (LVEDD) (MD = −4.09, 95%CI: −4.91 to −3.27), p < 0.00001), left ventricular end-systolic diameter (LVESD) (MD = −4.73, 95%CI: −5.63 to −3.84), p < 0.00001) and BNP (MD = −101.09, 95%CI: -132.99 to −69.18), p < 0.00001), and also superior in reducing hypersensitive-C-Reactive Protein (hs-CRP) (MD = −3.78, 95%CI: −4.35 to −3.21), p < 0.00001), Interleukin- 6 (IL-6) (MD = −25.92, 95%CI: −31.35 to -20.50), p < 0.00001), tumor necrosis factor-α (TNF-α) (MD = -5.04, 95%CI: −6.13 to −3.95), p < 0.00001), high mobility group protein B1 (HMGB1) (MD = −4.34, 95%CI: −5.22 to −3.46), p < 0.00001), and adverse reactions (ARs) (RR = 0.70, 95%CI: 0.51–0.97), p = 0.03). The GRADE evidence quality rating presented with moderate or low quality of evidence for the available data.Conclusion: Compared with the control group, QQC combined with CWM may be effective in treating DCM. However, the conclusion of this study must be interpreted carefully due to the inferior quality and ambiguity of bias in the included trials.Systematic Review Registration: https://www.crd.york.ac.uk/prospero, identifier [CRD42022297906].

show abstract

Section: Discussionsupporting

confidence: 90%

Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials

Wei

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In pursuit of finding novel therapy of CH and heart failure, various natural product based preparations are also empirically used due to the evidences of their efficacy, minimal side effects, affordability, and wide acceptability, especially for the people beyond the western hemisphere (Van Galen, 2014;Rastogi et al, 2016). A number of traditional Chinese medicines like QSYQ and Danshensu (Salvia miltiorrhiza) have shown cardio-protective effect in many experimental sets up (Zhu et al, 2016;Hao et al, 2017;Layne and Ferro, 2017).…”

Section: Introductionmentioning

confidence: 99%

Transcriptomic Validation of the Protective Effects of Aqueous Bark Extract of Terminalia arjuna (Roxb.) on Isoproterenol-Induced Cardiac Hypertrophy in Rats

et al. 2019

View full text Add to dashboard Cite

show abstract

“…12 The diagnostic values circulating miRNAs in plasma for DVT have been explored previously, and they are confirmed of correlation with the markers of hypercoagulability. 13 MicroRNA-335-5p (miR-335-5p) is reported to be transcribed in the genomic region of chromosome 7q32.2, 14 and it is closely associated with inflammatory responses, cell proliferation and migration. 15 Simultaneously, plasminogen activator inhibitor-1 (PAI-1) is a key member of the serine protease inhibitor family, and is involved in the fibrinolytic system and plasmin generation.…”

mentioning

confidence: 99%

Retracted: MicroRNA‐335‐5p suppresses lower extremity deep venous thrombosis by targeted inhibition of PAI‐1 via the TLR4 signalingpathway

Bao

Zhang

Wang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study aims to investigate the effects of microRNA-335-5p (miR-335-5p) on lower-extremity deep vein thrombosis (LEDVT) by targeting PAI-1 through the TLR4 signaling pathway in rat models. siRNA, mimic, and inhibitor were used for transfection. The miR-335-5p expression was detected by in situ hybridization. CCK-8 assay and flow cytometry were adopted to detect proliferation, cell cycle, and apoptosis, respectively. Scratch test and Matrigel-based tube formation assay were used to detect the effect of miR-335-5p on cell migration ability and tube formation ability. A miR-335-5p lentivirus plasmid was constructed and injected into LEDVT rats. The length and weight of thrombus were measured, changes of thrombus recanalization were observed by CD34 immunohistochemistry, and levels of PAI-1 and inflammatory factors in femoral vein blood were detected by ELISA. LEDVT rats showed a higher AOD value of PAI-1, higher expression of PAI-1, NF-κB, Rac1, IL-1β, and TLR4 and a lower miR-335-5p expression. PAI-1 and miR-335-5p were negatively correlated. Compared to the blank and siRNA-NC groups, the miR-335-5p mimic and siRNA-PAI-1 groups showed declined expression of PAI-1, TLR4, NF-κB, Rac1, and IL-1β, increased proliferation and tube formation abilities, less cells in G0/G1 phase, and decreased apoptosis, decreased length and weight of thrombus, organized thrombus, increased new blood vessels, and decreased levels of PAI-1, IL-1, IL-6, and Tnf-a. miR-335-5p may suppress the occurrence and development of LEDVT in rats by repressing the activation of the TLR4 signaling pathway by targeted inhibition of PAI-1.

show abstract

Oral Chinese Herbal Medicine for Treatment of Dilated Cardiomyopathy: A Systematic Review and Meta‐Analysis

Cited by 10 publications

References 9 publications

Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials

Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials

Transcriptomic Validation of the Protective Effects of Aqueous Bark Extract of Terminalia arjuna (Roxb.) on Isoproterenol-Induced Cardiac Hypertrophy in Rats

Retracted: MicroRNA‐335‐5p suppresses lower extremity deep venous thrombosis by targeted inhibition of PAI‐1 via the TLR4 signalingpathway

Contact Info

Product

Resources

About